Payment overview · 2025
General Payments
$708.21
45 reported records · 11 companies
Healthcare provider profile · identity verified
Brian A. Hyman, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · STATE COLLEGE, PA · NPI 1467415315
Verified facts
What the public records show
CMS Open Payments records show Brian A. Hyman, M.D. received $708.21 in general payments during 2025 across 45 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Qulipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $269.49 | 38.0% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $259.05 | 36.6% | 16 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $34.10 | 4.8% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.25 | 3.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.17 | 3.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $19.21 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.45 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.15 | 2.6% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $17.72 | 2.5% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $15.15 | 2.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.47 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $708.21 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $269.49 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $191.79 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $178.28 | 12 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $67.26 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 436 | 98 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 400 | 122 |
| Gabapentin | Gabapentin | 366 | 87 |
| Memantine Hcl | Memantine Hcl | 269 | 65 |
| Topiramate | Topiramate | 208 | 46 |
| Lamotrigine | Lamotrigine | 195 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 40 |
| Levetiracetam | Levetiracetam | 183 | 38 |
| Pregabalin | Pregabalin | 144 | 29 |
| Primidone | Primidone | 127 | 33 |
| Propranolol Hcl Er | Propranolol Hcl | 118 | 30 |
| Clonazepam | Clonazepam | 105 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 24 |
| Baclofen | Baclofen | 79 | 24 |
| Emgality Pen | Galcanezumab-Gnlm | 73 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 70 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 70 | 11 |
| Oxcarbazepine | Oxcarbazepine | 67 | 12 |
| Lacosamide | Lacosamide | 65 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 64 | 18 |
| Nurtec Odt | Rimegepant Sulfate | 58 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 55 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | 17 |
| Rytary | Carbidopa/Levodopa | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 15 |
| Sertraline Hcl | Sertraline Hcl | 49 | 12 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 45 | 11 |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | 11 |
| Zonisamide | Zonisamide | 42 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Carbamazepine Er | Carbamazepine | 37 | suppressed |
| Amantadine | Amantadine Hcl | 35 | 11 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Entacapone | Entacapone | 31 | suppressed |
| Keppra | Levetiracetam | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Qulipta | Atogepant | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 11 |
| Kesimpta Pen | Ofatumumab | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Modafinil | Modafinil | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Clobazam | Clobazam | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Diazepam | Diazepam | 14 | 13 |
| Briviact | Brivaracetam | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Rufinamide | Rufinamide | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Topamax | Topiramate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $708.21 · 45 records | Teva Pharmaceuticals USA, Inc. | AMYVID, AUSTEDO XR, BOTOX, Cologuard Collection Kit, INGREZZA, KISUNLA, LEQEMBI, Ocrevus, Ocrevus Zunovo, Ozempic, QULIPTA, UBRELVY, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYEPTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error